Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.
Mark D Minden, Donna E Hogge, Scott J Weir, Jim Kasper, Debra A Webster, Lavonne Patton, Yulia Jitkova, Rose Hurren, Marcela Gronda, Carolyn A Goard, Lian G Rajewski, John L Haslam, Kathleen E Heppert, Kevin Schorno, Hong Chang, Joseph M Brandwein, Vikas Gupta, Andre C Schuh, Suzanne Trudel, Karen W L Yee, Gregory A Reed, Aaron D Schimmer
American journal of hematology 2014;89(4):363-8